Diabetes drug tested to protect transplanted kidneys
NCT ID NCT04906213
Summary
This study tested whether a diabetes medication called empagliflozin could help protect the heart and kidneys of people who had received a kidney transplant. It involved 72 transplant recipients, half with type 2 diabetes and half without. Participants were randomly assigned to take either the drug or a placebo for 18 months to see its effects on kidney function, heart structure, and blood sugar levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.